Agilent Technologies

Articles

Agilent Applications for Biopharmaceutical Development and QA/QC

October 18, 2021

These applications will help you find the right solution for your analytical needs. Agilent solutions build confidence and reliability in all your analytical measurements.

Accurate Assessment of Oligo Purity

October 18, 2021

Partner with Agilent, benefit from industry-leading nucleic acid experience to advance lead oligo candidates from clinic to market with a goal of patient health and safety.

Fluorescence Measurement of Hybridization Between Quencher (DABCYL)-Labeled PNA Probes and a Fluorescein Labeled DNA Using the Fluorescence BioMelt Package

October 18, 2021

In living cells, the process of reversible hybridization is a critical requirement to the process of replication, transcription and translation.

High-Throughput Mass Spec Analysis of Synthetic Oligos

October 18, 2021

The appetite for higher throughput analytical methods has increased in the past years alongside the acceleration of oligo production and use.

Fast and High-Resolution Reversed-Phase Separation of Synthetic Oligonucleotides

October 18, 2021

Synthetic DNA- and RNA-based oligonucleotides are among many successful biotherapeutic drugs to treat many different kinds of illnesses.

Direct Analysis of In-Process Oligonucleotides without Manual Purification

October 18, 2021

Oligonucleotides synthesized using phosphoramidite chemistry are analyzed and purified using ion-pair reversed-phase liquid chromatography and anion-exchange chromatography.

Direct Analysis of Oligos Without Manual Purification

October 18, 2021

Oligonucleotides synthesized using phosphoramidite chemistry are analyzed and purified using ion-pair reversed-phase liquid chromatography and anion-exchange chromatography.

Purification of Single-Stranded RNA Oligonucleotides Using High-Performance Liquid Chromatography

October 18, 2021

The purification of oligonucleotides (ONs) can be particularly challenging because of the high similarity of target and impurities.

Analysis of mRNA Poly-A Sequence Variants by High-Resolution LC–MS

October 18, 2021

The urgency caused by the SARS-CoV-2 pandemic of 2020 prompted policy makers and pharmaceutical firms alike to develop and deploy mRNA vaccines with unprecedented speed.